Funding
Seed · Biotech

Healome Therapeutics raises £2m seed round for ocular therapies

Empirical Ventures, DEBRA Research, Cure EB, Oshen Bio and SFC Capital participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Healome Therapeutics raised £2 million in seed financing on July 7. Participants included Empirical Ventures, DEBRA Research, Cure EB, Oshen Bio and SFC Capital. The company develops eye-drop matrix technology for ocular-surface diseases.

Funding history

Seed · This round£2M

Sources

  1. Healome Therapeuticsprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related